Difference between revisions of "Value frameworks"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) m (Text replacement - "http://www.esmo.org/" to "https://www.esmo.org/") |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| + | Note that the structure and content of HemOnc.org are constantly undergoing evolution, such that information that you read here might be outdated. This page was last reviewed and updated in '''December 2023'''. | ||
=Introduction= | =Introduction= | ||
| Line 10: | Line 11: | ||
*'''2018:''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158764/ A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)] | *'''2018:''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158764/ A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)] | ||
| − | =[ | + | =[https://www.esmo.org/Policy/Magnitude-of-Clinical-Benefit-Scale ESMO Magnitude of Clinical Benefit Scale]= |
*'''2015 (Version 1.0):''' [https://annonc.oxfordjournals.org/content/26/8/1547.full.pdf+html A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)] [https://pubmed.ncbi.nlm.nih.gov/26026162/ PubMed] | *'''2015 (Version 1.0):''' [https://annonc.oxfordjournals.org/content/26/8/1547.full.pdf+html A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)] [https://pubmed.ncbi.nlm.nih.gov/26026162/ PubMed] | ||
*'''2017 (Version 1.1):''' [https://watermark.silverchair.com/mdx310.pdf ESMO-Magnitude of Clinical Benefit Scale version 1.1] | *'''2017 (Version 1.1):''' [https://watermark.silverchair.com/mdx310.pdf ESMO-Magnitude of Clinical Benefit Scale version 1.1] | ||
Latest revision as of 17:45, 23 June 2024
Note that the structure and content of HemOnc.org are constantly undergoing evolution, such that information that you read here might be outdated. This page was last reviewed and updated in December 2023.
Introduction
Several leading hematology/oncology societies and organizations have put forth value frameworks. Conceptually, these are approaches which are intended to combine measures of efficacy, toxicity, quality of life, and financial toxicity into a metric of value that can be used to influence treatment decisions. Our coverage of value frameworks will expand over time.
ASCO Value Framework
- 2015: American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- 2016: Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received PubMed
ESCAT
ESMO Magnitude of Clinical Benefit Scale
- 2015 (Version 1.0): A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) PubMed
- 2017 (Version 1.1): ESMO-Magnitude of Clinical Benefit Scale version 1.1
NCCN Evidence Blocks
- 2016: NCCN Evidence Blocks PubMed
Comparisons
ASCO Value Framework vs. ESMO-MCBS
- 2017: Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit? PubMed
ASCO Value Framework vs. NCCN Evidence Blocks
- 2017: Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology PubMed
Frequently asked questions
Q: Do you plan to add value measures to HemOnc.org?
A: At some point in the future, we may add value measures to some regimens; however, given that these frameworks are recently introduced and undergoing frequent revision, we will continue to monitor their development, for now.